Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RARE

Ultragenyx Pharmaceutical Inc

Mar 13 • 04:00PM ET

39.25

Dollar change -1.04
Percentage change -2.58	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX ALNY BMRN AMGN REGN IONS CRSP NBIX PBYI

| Held by: VTI VB VXF VBK XBI IWP IBB SCHA IWF IWR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.34	Insider Own	6.75%	Shs Outstand	92.41M	Perf Week	-1.92%
Market Cap	3.63B	Forward P/E	-	EPS next Y	-3.64	Insider Trans	-2.94%	Shs Float	86.26M	Perf Month	-9.94%
Income	-569.18M	PEG	-	EPS next Q	-1.56	Inst Own	95.14%	Short Float	5.32%	Perf Quarter	-20.42%
Sales	560.23M	P/S	6.48	EPS this Y	16.40%	Inst Trans	0.41%	Short Ratio	5.25	Perf Half Y	-29.56%
Book/sh	2.76	P/B	14.21	EPS next Y	30.87%	ROA	-37.94%	Short Interest	4.59M	Perf Year	-19.09%
Cash/sh	6.67	P/C	5.89	EPS next 5Y	69.25%	ROE	-214.50%	52W Range	37.02 - 60.37	Perf YTD	-6.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.45%	ROI	-51.50%	52W High	-34.98%	Beta	0.56
Dividend TTM	-	Quick Ratio	2.24	Sales past 5Y	48.58%	Gross Margin	79.96%	52W Low	6.02%	ATR (14)	1.74
Dividend Ex-Date	-	Current Ratio	2.37	EPS Y/Y TTM	23.93%	Oper. Margin	-95.67%	RSI (14)	41.14	Volatility	4.28% 4.49%
Employees	1294	Debt/Eq	3.56	Sales Y/Y TTM	29.01%	Profit Margin	-101.60%	Recom	1.20	Target Price	93.30
Option/Short	Yes / Yes	LT Debt/Eq	3.33	EPS Q/Q	8.20%	Payout	-	Rel Volume	0.51	Prev Close	40.29
Sales Surprise	8.57%	EPS Surprise	-6.23%	Sales Q/Q	29.42%	Earnings	Feb 13 AMC	Avg Volume	873.97K	Price	39.25
SMA20	-5.12%	SMA50	-7.25%	SMA200	-16.82%	Trades		Volume	446,339	Change	-2.58%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy	$162
Jun-04-21	Resumed	Robert W. Baird	Neutral	$109
May-06-21	Upgrade	Evercore ISI	In-line → Outperform	$144
May-06-21	Upgrade	Citigroup	Neutral → Buy	$160 → $151

Show Previous Ratings

Feb-24-25 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire)
Feb-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-18-25 08:00AM	Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Feb-14-25 09:48AM	Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
02:23AM	Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
04:19PM	Loading…
Feb-13-25 04:19PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update (GlobeNewswire)
Feb-06-25 04:30PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update (GlobeNewswire)
08:21AM	Ultragenyx announces new data on UX111 AV gene therapy (TipRanks)
Feb-05-25 08:00AM	Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS (GlobeNewswire)
Jan-17-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:14AM	Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential (Insider Monkey)
Jan-15-25 02:05PM	Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside (Benzinga)
Jan-12-25 11:00AM	Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones (GlobeNewswire)
Jan-06-25 04:30PM	Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:07AM	Loading…
08:07AM	Ultragenyxs Evkeeza secures EU approval for young children with rare cholesterol disorder (Pharmaceutical Technology)
02:00AM	European Commission (EC) Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Dec-20-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03:00AM	NHS England Rolls Out Evkeeza (evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) (GlobeNewswire)
Dec-19-24 04:05PM	Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome (GlobeNewswire)
08:00AM	Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Nov-26-24 04:30PM	Ultragenyx to Participate in Investor Conferences in December (GlobeNewswire)
Nov-20-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-24 10:30AM	Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit (GlobeNewswire)
Nov-06-24 02:27AM	Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... (GuruFocus.com)
Nov-05-24 04:11PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Nov-01-24 09:16AM	What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? (Insider Monkey)
Oct-29-24 04:05PM	Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Oct-18-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Oct-07-24 08:00AM	Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Oct-03-24 04:30PM	Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease (GlobeNewswire)
Sep-26-24 08:00AM	Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting (GlobeNewswire)
Sep-18-24 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 04:30PM	Ultragenyx to Participate in Investor Conferences in September (GlobeNewswire)
Aug-21-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.62%
Aug-06-24 10:45AM	3 Genomics Stocks That May Transform Personalized Medicine (InvestorPlace)
Aug-02-24 08:15AM	Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD Global Investments LP (Business Wire) +14.31%
07:44AM	Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up (Zacks)
Aug-01-24 04:17PM	Ultragenyx: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Jul-25-24 04:05PM	Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Jul-24-24 08:00AM	Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium (GlobeNewswire)
Jul-22-24 04:27PM	Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong (Investor's Business Daily)
Jul-19-24 04:05PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-18-24 09:03AM	Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans (Zacks)
Jul-17-24 04:05PM	Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program (GlobeNewswire)
Jun-20-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-17-24 03:27PM	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline (InvestorPlace)
Jun-13-24 08:49PM	Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -9.44%
10:15AM	Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug (Zacks)
05:12AM	Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last? (Zacks)
03:14AM	Insider Sale: EVP and Chief Legal Officer Karah Parschauer Sells Shares of Ultragenyx ... (GuruFocus.com)
Jun-12-24 04:05PM	Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +7.83%
04:00PM	Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
10:46AM	Ultragenyx (RARE) Posts New Data From Bone Disease Study (Zacks)
07:45AM	Ultragenyx, Mereo drug reduces fractures in bone disorder study (BioPharma Dive)
Jun-11-24 05:47PM	Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Jun-04-24 04:05PM	Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-31-24 10:36AM	Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study (Zacks)
May-30-24 04:00PM	Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
May-22-24 02:27PM	Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells (Benzinga)
May-17-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-24 04:30PM	Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference (GlobeNewswire)
May-04-24 10:24AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:01PM	Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ... (GuruFocus.com)
12:22PM	Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks)
May-02-24 08:58PM	RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:00PM	Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:49PM	Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ... (GuruFocus.com)
05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:08PM	Ultragenyx: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-30-24 04:00PM	Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease (GlobeNewswire)
08:00AM	Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
Apr-25-24 04:30PM	Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-19-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-16-24 11:33AM	Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study (Zacks)
Apr-15-24 07:30AM	Ultragenyx says Angelman therapy is working, but safety questions remain (BioPharma Dive) -8.79%
07:00AM	Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 (GlobeNewswire)
Apr-12-24 04:22PM	Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome (GlobeNewswire) -7.30%
08:00AM	Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Mar-22-24 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-24 08:11AM	10 NASDAQ Stocks with Biggest Upside (Insider Monkey)
Mar-12-24 05:00PM	Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ... (GuruFocus.com)
Mar-11-24 03:00PM	Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE) (GuruFocus.com)
Mar-08-24 09:38AM	10 Biotech Stocks with Huge Potential (Insider Monkey)
Feb-27-24 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire) +6.79%
Feb-23-24 04:05PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-24 10:43AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.75%
10:35AM	Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
07:53AM	Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat (Zacks)
Feb-15-24 04:15PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Feb-13-24 01:36PM	15 Best Strong Buy Stocks To Invest In (Insider Monkey) -5.91%
Feb-08-24 04:00PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Feb-06-24 08:00AM	Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Feb-05-24 04:05PM	Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome (GlobeNewswire)

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Horn Howard	Chief Financial Officer	Mar 06 '25	Sale	40.40	1,785	72,114	106,169	Mar 10 12:53 PM
Kassberg Thomas Richard	CBO & EVP	Mar 03 '25	Sale	42.10	6,028	253,779	265,238	Mar 04 08:19 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 03 '25	Sale	42.10	12,846	540,817	75,287	Mar 04 08:18 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 03 '25	Sale	42.10	8,945	376,584	71,922	Mar 04 08:16 PM
Pinion John Richard	See Remarks	Mar 03 '25	Sale	42.10	14,439	607,882	107,766	Mar 04 08:12 PM
KAKKIS EMIL D	President & CEO	Mar 03 '25	Sale	42.10	73,434	3,091,571	641,731	Mar 04 08:10 PM
KAKKIS EMIL D	President & CEO	Feb 28 '25	Sale	42.48	25,000	1,062,000	2,158,985	Mar 04 08:10 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 03 '25	Sale	42.10	15,103	635,836	87,855	Mar 04 08:06 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 03 '25	Sale	42.10	967	40,711	50,265	Mar 04 08:00 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Feb 27 '25	Sale	42.88	2,990	128,224	54,991	Mar 03 01:58 PM
KAKKIS EMIL D	Officer	Feb 28 '25	Proposed Sale	42.48	25,000	1,062,100		Feb 28 04:11 PM
Parschauer Karah Herdman	Officer	Feb 27 '25	Proposed Sale	42.88	2,990	128,215		Feb 27 05:08 PM
KAKKIS EMIL D	President & CEO	Dec 30 '24	Sale	42.23	11,727	495,231	2,183,985	Dec 31 02:05 PM
KAKKIS EMIL D	Officer	Dec 30 '24	Proposed Sale	42.23	11,727	495,264		Dec 30 04:32 PM
KAKKIS EMIL D	President & CEO	Dec 10 '24	Sale	50.00	8,273	413,650	2,195,712	Dec 11 06:44 PM
KAKKIS EMIL D	Officer	Dec 10 '24	Proposed Sale	50.00	8,273	413,650		Dec 10 04:12 PM
Horn Howard	Chief Financial Officer	Oct 10 '24	Sale	52.76	7,465	393,853	92,301	Oct 11 04:48 PM
KAKKIS EMIL D	President & CEO	Sep 03 '24	Sale	55.85	20,000	1,117,000	2,223,985	Sep 05 11:53 AM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 03 '24	Sale	56.19	91	5,113	41,551	Sep 05 11:50 AM
KAKKIS EMIL D	Officer	Sep 03 '24	Proposed Sale	55.85	20,000	1,117,096		Sep 03 04:40 PM
KAKKIS EMIL D	President & CEO	Aug 06 '24	Sale	50.17	20,000	1,003,400	2,243,985	Aug 07 02:48 PM
KAKKIS EMIL D	Officer	Aug 06 '24	Proposed Sale	50.17	20,000	1,003,418		Aug 06 04:28 PM
Sanders Corazon (Corsee) D.	Director	Jul 02 '24	Sale	40.98	584	23,932	12,009	Jul 03 02:07 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Jun 12 '24	Sale	45.00	9,806	441,270	57,981	Jun 12 07:47 PM
Sanders Corazon (Corsee) D.	Director	Jun 10 '24	Sale	41.10	1,737	71,391	7,248	Jun 10 07:58 PM
Crombez Eric	EVP and Chief Medical Officer	May 02 '24	Sale	43.66	354	15,456	48,431	May 03 03:23 PM
Crombez Eric	EVP and Chief Medical Officer	Apr 18 '24	Sale	44.10	142	6,262	48,785	Apr 19 04:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RARE

Ultragenyx Pharmaceutical Inc

Upgrade your FINVIZ experience